Hashtag
Men's Weekly

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum

MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The forum is taking place Sunday, January 8, 2022, as part of the activities surrounding the annual J.P. Morgan Healthcare Conference.

At the conference, Dr. Stamler will be featured on a panel entitled, "New Approaches to Parkinson's and Movement Disorders." He will also present a company update and participate in investor and business development meetings.

The program for the 6th Annual NIF is designed to cover the latest developments in global bio-partnering and investment, with additional panels covering scientific advances in key therapeutic areas of neurodegenerative diseases and CNS more broadly, which includes neuropsychiatry, ophthalmology, neurotech and digital therapeutics.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company's web site at www.alteritytherapeutics.com.

 Authorisation & Additional information

This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-participate-in-the-sachs-associates-6th-annual-neuroscience-innovation-forum-301712033.html

Authors: PR Newswire

Read more https://www.prnasia.com/story/archive/3976287_CN76287_0

Health & Wellness

Experience ultimate comfort: the health benefits of an adjustable bed and mattress

Hashtag.net.au - avatar Hashtag.net.au

Imagine waking up each morning feeling truly refreshed, without the usual aches and stiffness. For many, a traditional flat bed can fall short in providing the tailored support needed for optimal rest...

Why NDIS Cleaning Services Boost Health, Safety & Independence

Hashtag.net.au - avatar Hashtag.net.au

For many Australians living with a disability, maintaining a clean and safe home can be challenging. Everyday cleaning tasks-like vacuuming, mopping, sanitising kitchens, or bathrooms-may pose physica...

Why Choosing a GP Bundoora Is Key to Consistent and Preventive Healthcare

Hashtag.net.au - avatar Hashtag.net.au

Access to dependable primary healthcare is essential for maintaining long-term wellbeing. Choosing a trusted GP Bundoora allows individuals and families to receive ongoing medical support close to h...